Conference Reports for NATAP

The Liver Meeting Washington DC October 2017 Back

NAFLD Debrief AASLD 2017       Reported by Jules Levin   Kymberly D. Watt, MD Associate Prof. of Medicine Medical director of Liver Trasplantation Mayo Clinic, Rochester, MN AASLD: Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17) AASLD: The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17) AASLD: Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17) AASLD: Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17) AASLD: Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17) AASLD: BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17) AASLD: Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)